Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
|Videos|September 17, 2021
Dr. Matulewicz discusses underreported smoking status in GU cancer trials
Author(s)Urology Times staff
Advertisement
In this video, Richard Matulewicz, MD, MS, explains potential factors in underreported smoking status for GU cancer patients in clinical trials. Matulewicz is an assistant professor in the department of urology at Memorial Sloan Kettering Cancer Center, New York City.
Advertisement
Related to this article
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
3
Infertility care: Examining geographic gaps in access
4
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
5